Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2025-12-17 00:00:00 ET · period of report 2025-12-15 · accession 0001384243-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-17 | 2025-12-15 | KNSA | Quart Barry D | Dir | S - Sale+OE | $41.51 | -20.1K | 12.5K | -62% | -$835.6K |
| D | 2025-12-17 | 2025-12-15 | KNSA | Quart Barry D | Dir | M - OptEx | $10.36 | +20.1K | 32.7K | +160% | +$208.5K |
| D | 2025-12-17 | 2025-12-15 | KNSA | Quart Barry D | Dir | M - OptEx | $0.00 | -20.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2025-12-15 | S | D | 20,129 | $41.51 | 12,546 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.19 and $41.78. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |
| 2 | Common | Class A Ordinary Share | 2025-12-15 | M | A | 20,129 | $10.36 | 32,675 | D | — | — | |
| 3 | Derivative | Share Option | 2025-12-15 | M | D | 20,129 | $0.00 | 0 | D | $10.36 · — to 2028-02-29 | 20,129 Class A Ordinary Shares | (F3) The option is fully vested and exercisable. |